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Abstract To study brain free amino acids and their
relation with dementia we measured, by high-performance
liquid chromatography (HPLC), the concentration of eight
free amino acids, amines and related compounds. We used
temporal cortex (TC) samples obtained from 13 Alzhei-
mer’s disease (AD) patients and an equal number of age-
matched controls (AC). The patterns of free amino acids,
amines and related compounds showed significant quanti-
tative changes in AD conditions with respect to healthy
ones. In Alzheimer patients, lower levels of GABA were
found in the TC (-57 %). Amino acids glutamate (Glu),
and aspartate (Asp) concentrations, also appeared signifi-
cantly reduced in the TC of AD patients (Glu: -30 %;
Asp: -40 %) when compared with controls. The signifi-
cant gap between methionine (Met: -30 %) and cystathi-
onine (Cysta: ?60 %) levels in TC of AD people to
controls, might suggest an under/over activity of the
transmethylation and transsulphuration pathways, respec-
tively. Glutamine (Gln) and Urea were an exception to this
trend because their content was higher in AD patients than
in controls. Albeit these compounds may have particular
physiological roles, including the possible mediation of
synaptic transmission, changes in amino acid levels and
related compounds (detected in steady state) suggest a
modified metabolic status in brains of AD patients that
reveals a reduced function of synaptic transmission.
Because several evidences show that patients might display
quite different concentrations of neurotransmitters in brain
areas, assessing metabolites in different and well-charac-
terized AD stages should be investigated further.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by a global impairment of higher cognitive
functions mostly related to failure of synaptic connections
long before neurons die [1]. Studies conducted on ante-
mortem cerebral biopsy in neocortex of patients with AD
show not only that neurotransmitter systems (cholinergic,
noradrenergic, serotonergic and glutamergic neurons) and
pyramidal neurons are prematurely damaged in the course
of the disease [2], but also that the loss of cholinergic and
pyramidal neurons is related to the severity of dementia
evolution [3]. The molecular etiology of AD is still
incomplete. Neuronal death can occur by either apoptotic
or necrotic mechanisms [4]. All studies on humans with
AD indicate the amyloid-b-peptide (AbP) accumulation in
the cerebral cortex as an early and invariant event in the
development of AD pathology, preceding other brain
lesions and clinical symptoms by many years or decades
[5]. Despite extensive research, today the primary events
underlying the neuropathological changes are still like
pieces of a puzzle that cannot be fitted together. Thus, in
view of the importance of collecting more useful infor-
mation on the biochemical features characterizing the
neurodegeneration in AD, we analyzed the variations in the
patterns of free amino acids and related compounds in
brain extracts in the disease with respect to AC. In the light
of previous works on this matter [6], the described data are
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also employed to establish a correlation between such
amino acids variation and the modification of their
function.
Materials and methods
Brain specimens in AC and AD neuropathologically con-
firmed cases (see Table 1) have been used to determine the
amino acid level patterns and related compounds. Brain
tissue samples (temporal cortex, grey matter) were received
from the MRC London Brain Bank for Neurodegenerative
Diseases, Department of Neuropathology, Institute of
Psychiatry, London, UK. The AD patients fulfilled the
National Institute of Neurological and Communicative
Disorders and Stroke and Alzheimer’s Disease and Related
Disorders Association (NINCDS/ADRDA) criteria for
probable AD [7]. The histological diagnosis of AD was
established and was consistent with the CERAD criteria [8]
for a sure diagnosis of AD. Control subjects had not any
history of dementia, nor other neurologic disease. Neuro-
pathologic examination confirmed the absence of any sig-
nificant gross or microscopic brain abnormalities in
controls. Specimens were transported to Palermo labora-
tory on dry ice and the freezing chain was never inter-
rupted. The brain samples were coded and kept frozen at
-70 C until used.
Amino acid standards, protease inhibitors, derivatization
reagents and other chemical reagents (A-grade or for
chromatographic use) were purchased from Sigma (Milan,
Italy).
AC and AD samples are weighed promptly with a
microbalance (Mettler-H72, Zurich, Switzerland), thawed
on ice, minced and then mechanically homogenized in an
ice-cold solution of 10 mM Hepes buffer, pH 7.4 con-
taining 137 mM NaCl; 4.6 mM KCl; 1.1 mM KH2PO4;
0.6 mM MgSO4 using a Wheaton Dounce tissue grinder.
To prevent artifactual proteolysis, the Protease Inhibitor
Cocktail (Sigma) is added to the mixture along with
0.2 mM dithiothreitol. Homogenate is then centrifuged at
12,000g for 20 min at 4 C with a Beckman L8-70M
refrigerated centrifuge. Supernatants are removed, depro-
teinized with 100 ll of sulfosalicylic acid (50 % solution),
and again centrifuged at 7,500g for 5 min at 4 C with an
ALC 4239R refrigerated centrifuge. The clear supernatants
are then withdrawn, filtered through Millipore Millex-HV
(0.45 lm) and used for the amino acids and related com-
pounds determination.
The free amino acids and related compounds contents of
brain specimens have been analyzed through a Beckman’s
System 6300 High-Performance Amino Acid Analyzer
(Beckman Coulter S.P.A. Milan, Italia) with the procedure
described by Borum [9] using an Li high-performance
column (10 cm) with the buffers Li A/Li B at a flow rate of
30 ml/min at 1,600 psi at a column temperature of
34–63 C. It has been used ninhydrin as a colorimetric
reagent. The analysis time is 53 min. Data integration has
been performed by a Shimadzu Chromatopac C-R3A.
Clinical and autopsy data are given in Table 1. Statistical
analysis has been performed using Primer of Biostatistics
(Stanton A. Glantz, McGraw-Hill-Libri, New York) and
Prism (GraphPad Software, San Diego, USA). Differences
between controls and pathological patients have been tes-
ted by independent two-sample t test with P \ 0.05
accepted as significant.
Results
As shown in the Table 2, a total of 10 different compounds
between free amino acids, amine species and related
compounds are determined in the TC brain of the AC and
AD patients. In general, almost all amino acids and
ammonia levels are significantly lower in AD when com-
pared with AC patients ones. It was found that Met levels
showed a decrease in about 30 % in AD patients with
respect of control values. When compared with AC,
GABA, Glu, Asp and ornithine (Orn) levels are markedly
and significantly decreased (-33, -30, -40, -62 %,
respectively) in TC of AD brain subjects. The change in
Cysta, urea and Gln levels are an exception to this trend,
their contents are greater in AD people (?63, ?124,
?60 %, respectively) than in AC cortex.
Another interesting evidence from chromatographic
analysis in pathological brain extracts is the lowered peaks
of ammonia (-25 %). The arginine (Arg) content in AD
group is slightly lower (-27 %) than in the AC.
Discussion
Interesting considerations emerge from the evaluation of
amino acids, amine patterns and related compounds from
soluble extracts in brain TC of patients affected by AD
Table 1 Characterization of study groups by number, age,
post-mortem interval, male-to-female ratio
Alzheimer patients Age-matched patients
N 13 13
Age (year) 71.1 ± 7.6 72.7 ± 9.7
Sex (m/f) 3/2 5/2
PMI (h) 30.09 ± 0.67 31.24 ± 0.58





when compared with AC. The data reveal some changes in
almost all amino acids levels detected at steady state. The
slightly decrease in Met levels in AD patients shows a
related deficit of brain structural proteins [10]. As for
amino acids, such as Asp, Glu and Met the damage con-
sequent to their decrease will not only lead to a changed
protein turnover in AD conditions, but also to a reduced
availability of the special metabolites or neurotransmitters
or precursors. When compared with the controls, Met
levels are significantly reduced in AD group thus we think
this drastic reduction could be the outcome of a metabolic
pathway disorder, but it could also be a cause. Met, in the
form of S-adenosylmethionine (SAM), is the principal
donor of methyl groups in numerous methyltransferase
reactions [11]. Met levels may be reduced through exces-
sive utilization in polyamine biosynthesis. Previous studies
have demonstrated markedly elevated SAM decarboxylase
activity, ornithine decarboxylase (ODC) protein and sper-
midine levels so far [12]. As reported, SAM levels are
severely decreased in AD patients’ brain and CSF [13].
Moreover, MAT2A gene expression in human hepatocar-
cinoma cells was modulated by Met deprivation through its
conversion into SAM [14]. Therefore, a Met decrease in
AD patients’ brain could also be an early signal or an
adaptive response to the change of its modified status, and
SAM level variation could be a key event for homeostasis
of the brain too. The quite different pattern between Cysta
levels in AD patients compared with AC caught our
attention. In fact, a high concentration of Cysta in the TC
of AD patients in our experimental conditions, was an
unexpected finding. The sharp Cysta levels could suggest
the existence in AD brains of a particular relationship
between the amount of the enzymes involved in the syn-
thesis by cystathionine b-synthase activity and in the
cleavage of the amino acid by c-cystathionase activity. As
reported, the human brains analysed by autopsy on normal
subjects contain a high concentration of Cysta [15]. The
presence of large amounts of Cysta in affected human brain
and in developing brain has been demonstrated [16]. Thus,
the surplus of Cysta level in AD brain could be used to
increase cysteine pool for glutathione synthesis, the major
redox buffer in mammalian cells [17, 18].
A decrease in Arg content, for instance, may have the
slowdown of the citrulline-NO cycle as a consequence
[19]. Furthermore, Arg decreases may partly explain a
reduced local synthesis of creatine together with the
markedly impaired activity of creatine kinase (CK) BB
isoform, detected in AD brains [20].
A marked decrease is observed in GABA neurotrans-
mitter in AD brain. GABA deficit in senile dementia is
associated with a decreased glutamate decarboxylase
activity [21]. It may be determined by a more active
catabolism from the glial GABA transaminase, but it may
also reflect the reduced availability of Glu, as our experi-
mental observations have shown. Gln is an exception to
this trend, its content being 1.6-fold greater in AD than in
AC cortex, but it only partially contributes to the Glu
homeostasis by the aging of the glutaminase activity. In
fact, graded reductions of glutaminase (GA) are combined
with increases in glutamine synthetase (GS) activity [22,
23]. Our results suggest an in vivo adaptation of the glu-
tamate–glutamine cycle to avoid neuronal death. The
increase in Gln level is a really expected result if the
observed activation of glia cells in neurodegeneration is
taken into consideration [24]. Hence, the GS activity
should be monitored as it seems behaving like a switch
under pathological conditions in brain. The decreased
content of Glu in AD TC suggests its possible withdrawal
to increase Gln levels in astrocytic cells. This agrees with
the previous data on decreased Glu and higher Gln content
reported for the same cortex area in AD postmortem brain
[25, 26]. A lower Asp concentration, for instance, is
detected in all AD temporal cortex specimens and we
consider it may be the result of a reduced Glu concentra-
tion, as in brain the main route of Asp biosynthesis is that
of glutamate–oxalacetate transamination.
Another interesting evidence from chromatographic
analysis in pathological brain extracts is the lowered peaks
of ammonia in AD brains. The lowered ammonia level,
together with its involvement in Gln biosynthesis, might be
the result of the remarkable increase in urea in brain
Table 2 Levels of L-amino acids and related compounds found in











Urea 13.8 ± 11.72a 6.16 ± 5.9 2.240
Aspartate (Asp) 1.80 ± 1.12a 3.00 ± 1.26 0.600
Glutamate (Glu) 4.90 ± 1.69a 7.02 ± 1.65 0.698
Glutamine (Gln) 2.68 ± 1.37a 1.67 ± 0.61 1.600
Methionine (Met) 0.23 ± 0.09a 0.32 ± 0.11 0.718
Cystathionine (Cysta) 0.80 ± 0.05a 0.49 ± 0.33 1.632
GABA 0.60 ± 0.16a 0.90 ± 0.28 0.666
Ammonia 0.15 ± 0.03a 0.20 ± 0.07 0.750
Ornithine (Orn) 0.03 ± 0.01a 0.08 ± 0.07 0.370
Arginine (Arg) 0.29 ± 0.14a 0.40 ± 0.11 0.725
Data are given as mean ± standard deviation (SD) found in temporal
cortex extracts from 13 Alzheimer patients and 13 normal subjects
Significance between groups was tested by two-sample independent
t test with P \ 0.05 accepted as significant
wwt wet weight tissue





pathological group. This increased level could be a conse-
quence of the altered urea diffusion in affected brain areas,
determined by permeability change of the blood–brain
barrier that causes its retention or a higher influx. It rather
appears more realistic to assume arginine broken down by
overexpressed arginase hetero-form to give unpredictable
urea levels in the brain. This may contribute to a dangerous
arginine depletion that may be a prerequisite for transla-
tional control of iNOS mRNA and NO generation [27]. A
marked decrease in ornithine (Orn) in AD could be the
virtual warning bell of a significantly increased inducible
ODC activity. A recent study has shown how an overex-
pression of ODC had caused cellular transformation, sug-
gesting that the key enzyme for polyamine biosynthesis
should be regarded as a proto-oncogene product [28].
Recent observations have showed an attempted re-entry
into the cell division cycle of the neurons in AD [29] and
since neuronal maturation is associated with effective
escape from the cell division cycle, emergence of quies-
cence may be deleterious. The current data analysis of free
amino acids in brain temporal cortex of AD individuals
once more points out some common aspects of the neuronal
damage. Furthermore, they solicit the question whether
such a dramatic amino acids variation may be almost
exclusively associated with an increased protein catabolism
by calpain and other proteases [30, 31], if it may also be due
to a deficient protein biosynthesis or excess brain protein
oxidation [10] (or to a long-term process imbalance).
The apparent deficit in amino acids and neurotransmit-
ters in AD degenerating brains may be a protective device
for a progressively reduced function, based on a long-term
adaptation mechanism which might start early in life.
Moreover, although not as widely appreciated, the regula-
tion of cellular functions by major (carbohydrates, fatty
acids, sterols) and minor (minerals, vitamins) dietary con-
stituents (including the control of the gene expression), is
well documented in prokaryotes and lower eukaryotes [32].
The idea amino acids can regulate gene expression in
mammalian cells has been considered [33]. Mammalian
cells can also adapt to dietary or pathological fluctuation in
amino acids availability. It has been shown that a number
of genes have specifically changed their expression levels
following amino acids deprivation [34]. Under such lim-
iting conditions, amino acids could be playing a signalling
role in affected brains, conveying regulatory messages to
the transcriptional machinery and affecting the turnover of
specific mRNA and proteins. For instance, limitation of
several amino acids greatly increases the expression of the
gene encoding growth factors, binding proteins, enzymes,
amino acids transport systems, retrograde tRNA transport
[35, 36]. Another possibility is that this deficit could be the
result of an ineffective attempt by brain tissues in repairing
or gathering energy. These observations, taken together,
suggest that a condition of amino acid stress anyway
caused can be crucial in starting changes in brain metabolic
status. Moreover, such an adaptive process involves both
neuron and glia populations, with an exaltation of glial
function with respect to neuron function as a consequence
of neuronal control loss [37]. To define if these present
findings are trait or state markers of AD it needs further
studies on brain samples obtained from AD patients with
well-characterized stages of disease.
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